ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1369

Persistence, Effectiveness and Treatment Patterns of Upadacitinib in over 2600 Australian Rheumatoid Arthritis Patients: A Retrospective Analysis from the OPAL Dataset

Peter Youssef1, Sabina Ciciriello2, Talib Tahir3, Tegan Smith4, Catherine O'Sullivan4, Joanna Leadbetter5, Belinda Butcher5, Nicole Walsh6, Miriam Calao6 and Geoffrey Littlejohn7, 1Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia, 2The University of Melbourne, Melbourne, Victoria, Australia, 3Coburg Rheumatology Service, Coburg, Victoria, Australia, 4OPAL Rheumatology Ltd, Geelong, Victoria, Australia, 5WriteSource Medical Pty Ltd, Lane Cove, New South Wales, Australia, 6AbbVie Pty Ltd, Mascot, New South Wales, Australia, 7Monash University, Clayton, Victoria, Australia

Meeting: ACR Convergence 2024

Keywords: Disease Activity, Disease-Modifying Antirheumatic Drugs (Dmards), rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: RA – Treatment Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: To describe the real-world treatment patterns, response and persistence in rheumatoid arthritis (RA) patients (pts) treated with upadacitinib (UPA).

Methods: This retrospective, non-interventional, multicenter cohort study used data from the OPAL dataset, derived from electronic medical records. Included pts were aged between 18 and 94 years, had a clinical diagnosis of RA and initiated UPA for the first time between May 2020 and March 2023. Pts were followed up to June 2023. Primary objective: Persistence (Kaplan-Meier methods) in the overall population, by line of therapy and as monotherapy and combination therapy. Secondary objectives included describing treatment patterns and clinical effectiveness, measured by DAS28CRP(3) (as observed). To descriptively compare outcomes in pts initiated at index with UPA monotherapy and UPA in combination with csDMARDs, pts were propensity score matched using age, sex, line of therapy, DAS28CRP(3) category, index year.

Results: Full Analysis Set (FAS) included 2,624 UPA pts (Table 1). At index, 27% of pts initiated UPA as monotherapy and 73% as combination therapy. 75% of UPA pts were female. Median age of pts was 61 years, with 41% aged ≥ 65 years. 66% were previously treated with b/tsDMARDs and, at index, 37% and 58% of pts were prescribed concomitant NSAID and corticosteroids, respectively. UPA pts had median follow-up of 18.2 months (95% CI 17.1 – 19.1 months), with median time on treatment of 26.6 months (95% CI 24.4 – 29.9 months). UPA persistence rates at 15 and 21 months were 64% (95% CI 62%-66%) and 56.5% (95% CI 54%-59%), respectively. UPA median time on treatment was greatest when used in 1st line (31.0 months in 1st line, 26.5 in 2nd line; 22.4 in ≥3rd line). Persistence rates at 21 months: 63% 1st line, 56% 2nd line, 52% ≥ 3rd line (Fig 1). In 2nd line UPA pts, median time on treatment was similar regardless of prior treatment being JAKi (median 25.3 [95%CI 16.1 – not reached] months) or TNFi (median 27.78 [95% CI 23.2 – 35.4] months). At index, 35% of UPA pts were in DAS28CRP(3) remission (10% in 1st line), increasing to 73% at 3 months (≥ 69% regardless of line of therapy) (Fig 1). The proportion of pts receiving UPA as monotherapy increased to ≥ 33% from 9 months post index.

The propensity score matched UPA monotherapy and UPA combination cohorts, included 706 pts each and were generally well matched (Table 1). Median time on treatment was similar for pts receiving at index UPA monotherapy or UPA combination (27.8 months [95% CI 23.5 to 33.4 months] and 30.4 [95% CI 22.1 to 35.3 months], respectively; p=0.84). At index, almost half of UPA monotherapy and combination matched pts were in DAS28CRP(3) remission, this increased to ≥70% from 3 months, independent of line of therapy (Fig 2).

Conclusion: Overall, RA patients persisted on UPA treatment for a median of > 2 years, with longer persistence in earlier lines of therapy. Pts initiating UPA as monotherapy or combination therapy showed similar persistence. UPA was effective irrespective of line of therapy and as either monotherapy or combination therapy, with increased remission rates as early as 3 months, reflective of observations from the UPA clinical trial program.

Supporting image 1

Table 1

Supporting image 2

Figure 1

Supporting image 3

Figure 2


Disclosures: P. Youssef: AbbVie Pty Ltd, 1, 6; S. Ciciriello: None; T. Tahir: None; T. Smith: OPAL Rheumatology, 3; C. O'Sullivan: OPAL Rheumatology, 3; J. Leadbetter: OPAL Rheumatology, 7; B. Butcher: OPAL Rheumatology, 7; N. Walsh: AbbVie Pty Ltd, 3, 11; M. Calao: AbbVie Pty Ltd, 3, 11; G. Littlejohn: AbbVie Pty Ltd, 1, 6.

To cite this abstract in AMA style:

Youssef P, Ciciriello S, Tahir T, Smith T, O'Sullivan C, Leadbetter J, Butcher B, Walsh N, Calao M, Littlejohn G. Persistence, Effectiveness and Treatment Patterns of Upadacitinib in over 2600 Australian Rheumatoid Arthritis Patients: A Retrospective Analysis from the OPAL Dataset [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/persistence-effectiveness-and-treatment-patterns-of-upadacitinib-in-over-2600-australian-rheumatoid-arthritis-patients-a-retrospective-analysis-from-the-opal-dataset/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/persistence-effectiveness-and-treatment-patterns-of-upadacitinib-in-over-2600-australian-rheumatoid-arthritis-patients-a-retrospective-analysis-from-the-opal-dataset/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology